News

Carilion CEO Nancy Howell Agee to Retire

Nancy Howell Agee, who led Carilion through more than a decade of transformative change, will step down as CEO Sept. 30. Steve Arner, who was promoted to president in May 2023, will succeed Agee and become president and CEO Oct. 1.

The leadership transition comes after Agee’s long and distinguished career at Carilion, beginning as a nurse in 1973. She was named Carilion’s president and CEO in 2011, becoming the health system’s seventh – and only female — top executive.

Agee earned national recognition for reorganizing Carilion as a fully integrated, physician-led clinic that includes a medical school and research institute with Virginia Tech, and served as chair of the American Hospital Association’s Board of Trustees in 2018.

She will serve as CEO emeritus through September 2025 and focus on philanthropy, growing Carilion’s partnerships and continuing to develop the health system’s reputation statewide and nationally.

Steve is a strong and capable leader whose commitment to our mission and deep knowledge of our entire organization make him well-suited for the CEO role,” said James Hartley, chairman of Carilion Clinic’s board of directors.

Arner has served as chief operating officer since 2012. He spearheaded more than $500 million in facilities investments, including the Crystal Spring Tower addition to Carilion Roanoke Memorial Hospital, on track for completion in 2025, and the recently opened Carilion Children’s and Mental Health facilities at Tanglewood. During the Covid-19 pandemic, he led the health system’s response, while also serving as chair of the Virginia Hospital and Healthcare Association.

“Carilion today is a nationally ranked academic health system that provides an extraordinary range of services, from primary care to the most advanced, complex care,” said Arner. “In some respects, it’s a far different organization than the one I joined more than 25 years ago. What has remained the same since the day I started is Carilion’s laser-like focus on its mission and our community, and I look forward to continuing on the path to growth and collaboration.”

Hartley added, “Carilion and our community have been the fortunate beneficiaries of Nancy’s talents for more than 50 years. I’m grateful to her for her continued service, and I’m grateful to Steve for advancing us to our next chapter.”

Read more here.

Recent News

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin

07/07/2026

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) announced it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the